Displaying 901 - 920 of 1605
Bi-Lo Holdings, LLC, In the Matter of
According to the FTC's complaint, Bi-Lo’s proposed $265 million acquisition of the Delhaize supermarkets would likely harm consumers through higher grocery prices, diminished quality and reduced service levels in 11 local markets in three states. The consent order requires the merged Bi-Lo/Delhaize to sell 12 stores to Rowes IGA Supermarkets, HAC, Inc., W. Lee Flowers & Co., Inc. and Food Giant. Under the terms of the purchase agreement, Bi-Lo will acquire the Delhaize stores on a rolling basis, through eight separate deal closings over a 10-week period. Each supermarket divestiture must be completed within 10 days of the respective Bi-Lo/Delhaize closing date. The FTC settlement preserves supermarket competition in 11 local markets in three states.
FTC Proposes to Study Merger Remedies
FTC Approves Final Order Barring Blue Rhino, AmeriGas from Restraining Competition
FTC Puts Conditions on Eli Lilly’s Proposed Acquisition of Novartis Animal Health
FTC Approves SCI’s Application to Divest Funeral Home in Auburn, California
Verisk/EagleView, In the Matter of
The FTC challenged Verisk Analytics, Inc.’s proposed $650 million acquisition of EagleView Technology Corporation, alleging that it would likely reduce competition and result in a virtual monopoly in the U.S. market for rooftop aerial measurement products used by the insurance industry to assess property claims. The FTC issued an administrative complaint and authorized staff to seek a temporary restraining order and preliminary injunction in federal court. On 12/16/14, Verisk Analytics, Inc. announced that it would abandon its plans to acquire EagleView, and the Commission dismissed the administrative complaint.
Service Corporation International and Stewart Enterprises, Inc., In the Matter of
Service Corporation International (SCI), the nation’s largest provider of funeral and cemetery services,agreed to sell 53 funeral homes and 38 cemeteries to resolve FTC charges that its proposed $1.4 billion acquisition of Stewart Enterprises, Inc. (Stewart) is likely to substantially lessen competition in 59 communities throughout the United States. The FTC complaint alleges the deal as proposed would eliminate direct competition between the two firms. The FTC charges that the proposed deal would enable the merged firm unilaterally to raise prices charged to consumers in these local markets and would substantially increase the risk of collusion between SCI and the few remaining competitors in the affected local areas. The proposed order settling the FTC’s charges requires SCI and Stewart to sell the 53 funeral homes and 38 cemeteries to Commission-approved buyers within 180 days, and also requires SCI and Stewart to sell certain related assets and property needed to ensure that the buyers will be able to fully replicate the competition that would have been lost if the transaction were completed as proposed.
Statement of FTC Bureau of Competition Director Deborah Feinstein on Verisk’s Decision to Drop Its Proposed Acquisition of EagleView Technology Corporation
FTC Challenges Verisk Analytics, Inc.’s Proposed Acquisition of EagleView Technology Corporation
Opinion: Antitrust Enforcement in Health Care – Controlling Costs, Improving Quality
FTC Requests Public Comments on Application from Owners of Surgery Center Holdings, Inc. for Approval to Divest Assets in Central Florida
FTC Puts Conditions on Medtronic’s Proposed Acquisition of Covidien
FTC Puts Conditions on Pharmaceutical Joint Venture Between GlaxoSmithKline and Novartis
Dissenting Statement of Commissioner Maureen K. Ohlhausen - In the Matter of AmeriGas and Blue Rhino
FTC Requires Divestiture as a Condition of Surgery Center Holdings' Acquisition of Competitor Symbion
Prestige Brands Holdings, Inc. and Insight Pharmaceuticals Corporation, In the Matter of
Pharmaceutical company Prestige Brands Holdings, Inc., the maker of Dramamine, agreed to divest assets and marketing rights for the over-the-counter motion sickness drug Bonine to settle FTC charges that Prestige’s proposed acquisition of Insight Pharmaceuticals Corporation would likely be anticompetitive. Prestige proposed to acquire Insight for $750 million. According to the FTC’s complaint, Prestige’s Dramamine, which is the best-selling branded product in the market for over-the-counter motion-sickness drugs, and Insight’s Bonine, are the only two branded products with significant sales. Absent a remedy, the acquisition would eliminate the close competition between Dramamine and Bonine, likely leading to higher prices for consumers.
Displaying 901 - 920 of 1605